AlphaCrest Capital Management LLC Buys 1,507 Shares of Humana Inc. (NYSE:HUM)

AlphaCrest Capital Management LLC grew its position in Humana Inc. (NYSE:HUMGet Rating) by 60.2% during the 2nd quarter, Holdings Channel reports. The firm owned 4,010 shares of the insurance provider’s stock after purchasing an additional 1,507 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Humana were worth $1,877,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in HUM. BlackRock Inc. grew its stake in Humana by 4.4% during the first quarter. BlackRock Inc. now owns 11,751,892 shares of the insurance provider’s stock worth $5,114,071,000 after buying an additional 497,536 shares during the last quarter. Vanguard Group Inc. increased its holdings in Humana by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 10,927,647 shares of the insurance provider’s stock valued at $4,755,384,000 after purchasing an additional 919,325 shares in the last quarter. Wellington Management Group LLP raised its position in Humana by 38.8% in the 1st quarter. Wellington Management Group LLP now owns 8,775,376 shares of the insurance provider’s stock valued at $3,818,781,000 after purchasing an additional 2,453,565 shares during the last quarter. Capital Research Global Investors boosted its stake in Humana by 7.6% in the first quarter. Capital Research Global Investors now owns 4,164,456 shares of the insurance provider’s stock worth $1,812,264,000 after purchasing an additional 292,456 shares in the last quarter. Finally, Capital International Investors grew its holdings in shares of Humana by 6.4% during the first quarter. Capital International Investors now owns 3,353,696 shares of the insurance provider’s stock worth $1,459,625,000 after purchasing an additional 201,702 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

Insider Activity at Humana

In other Humana news, CAO William Kevin Fleming sold 11,157 shares of the firm’s stock in a transaction that occurred on Thursday, November 3rd. The shares were sold at an average price of $565.61, for a total transaction of $6,310,510.77. Following the sale, the chief accounting officer now directly owns 2,542 shares in the company, valued at approximately $1,437,780.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO William Kevin Fleming sold 11,157 shares of the firm’s stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $565.61, for a total transaction of $6,310,510.77. Following the sale, the chief accounting officer now directly owns 2,542 shares in the company, valued at $1,437,780.62. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce D. Broussard sold 9,000 shares of the company’s stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $566.17, for a total transaction of $5,095,530.00. Following the completion of the transaction, the chief executive officer now directly owns 80,564 shares of the company’s stock, valued at $45,612,919.88. The disclosure for this sale can be found here. In the last three months, insiders sold 30,161 shares of company stock worth $16,994,804. 0.39% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on HUM shares. Wells Fargo & Company raised their price target on shares of Humana from $558.00 to $610.00 in a report on Tuesday, November 8th. Cowen boosted their target price on Humana from $547.00 to $647.00 in a research report on Monday, November 7th. Deutsche Bank Aktiengesellschaft upgraded Humana from a “hold” rating to a “buy” rating and raised their price target for the company from $514.00 to $576.00 in a report on Wednesday, October 26th. Truist Financial boosted their price objective on Humana from $570.00 to $650.00 in a report on Thursday, November 3rd. Finally, SVB Leerink raised their target price on shares of Humana from $540.00 to $640.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Humana currently has an average rating of “Moderate Buy” and a consensus target price of $579.00.

Humana Stock Performance

Shares of Humana stock opened at $538.30 on Thursday. The stock’s fifty day simple moving average is $515.70 and its 200 day simple moving average is $484.55. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $68.15 billion, a PE ratio of 24.41, a PEG ratio of 1.50 and a beta of 0.76. Humana Inc. has a 12 month low of $351.20 and a 12 month high of $571.30.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Stockholders of record on Friday, December 30th will be issued a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Thursday, December 29th. Humana’s dividend payout ratio (DPR) is presently 14.29%.

Humana Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMGet Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.